Literature DB >> 8749837

Predictors of response to amine-specific antidepressants.

R A Burns1, T Lock, D R Edwards, C L Katona, D A Harrison, M M Robertson, B Nairac, M T Abou-Saleh.   

Abstract

Discriminant function analysis of data from a double-blind comparative trial of lofepramine (a noradrenaline-specific reuptake inhibitor) and fluoxetine (a serotonin-specific reuptake inhibitor), involving 183 patients was used to identify predictors of response. Psychic anxiety significantly predicted a positive response to antidepressant medication, whereas psychomotor retardation, observed sadness, subjective lassitude and somatic complaints were significant predictors of nonresponse. Age, gender, endogenicity, duration of illness and number of previous episodes were not predictive of response. Significant differences were found between predictors of response to fluoxetine and lofepramine (P < 0.001 all groups). Predictors of response to lofepramine were similar to overall predictors, i.e., psychic anxiety predicted responders whilst observed sadness, psychomotor retardation, lassitude, inability to feel and somatic complaints predicted nonresponders. In contrast, baseline weight loss predicted response to fluoxetine, whereas anxiety, reduced insight and a tendency to blame others significantly predicted nonresponse. Such findings have practical implications for the management of depressive illness.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8749837     DOI: 10.1016/0165-0327(95)00039-9

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  7 in total

Review 1.  Role of pharmacogenomics in individualising treatment with SSRIs.

Authors:  Dalu Mancama; Robert W Kerwin
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 2.  Psychomotor retardation in depression: biological underpinnings, measurement, and treatment.

Authors:  Jeylan S Buyukdura; Shawn M McClintock; Paul E Croarkin
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2010-10-31       Impact factor: 5.067

3.  Sex-dependent modulation of treatment response.

Authors:  David R Rubinow; Molly Moore
Journal:  Dialogues Clin Neurosci       Date:  2004-03       Impact factor: 5.986

Review 4.  Fluoxetine for adults who are overweight or obese.

Authors:  Aurora E Serralde-Zúñiga; Alejandro G Gonzalez Garay; Yanelli Rodríguez-Carmona; Guillermo Melendez
Journal:  Cochrane Database Syst Rev       Date:  2019-10-15

Review 5.  Psychomotor retardation in depression: a systematic review of diagnostic, pathophysiologic, and therapeutic implications.

Authors:  Djamila Bennabi; Pierre Vandel; Charalambos Papaxanthis; Thierry Pozzo; Emmanuel Haffen
Journal:  Biomed Res Int       Date:  2013-10-30       Impact factor: 3.411

6.  Use of Fluoxetine to Reduce Weight in Adults with Overweight or Obesity: Abridged Republication of the Cochrane Systematic Review.

Authors:  Aurora E Serralde-Zuñiga; Alejandro G González-Garay; Yanelli Rodríguez-Carmona; Guillermo Meléndez-Mier
Journal:  Obes Facts       Date:  2022-06-02       Impact factor: 4.807

Review 7.  Predictors, moderators, and mediators (correlates) of treatment outcome in major depressive disorder.

Authors:  George I Papakostas; Maurizio Fava
Journal:  Dialogues Clin Neurosci       Date:  2008       Impact factor: 5.986

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.